Citicoline in Ischemic Stroke, a Randomized Trial - Trial NCT06210646
Access comprehensive clinical trial information for NCT06210646 through Pure Global AI's free database. This Phase 3 trial is sponsored by Kafrelsheikh University and is currently Recruiting. The study focuses on Ischemic Stroke. Target enrollment is 800 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Kafrelsheikh University
Timeline & Enrollment
Phase 3
Dec 29, 2023
Dec 29, 2024
Primary Outcome
Value of Montreal Cognitive Assessment (MoCA),Rate of drug-related complications after 6 months
Summary
Along with the current clinical trial, the efficacy and safety of a 1000 mg daily citicoline
 administered within 24 hours of the first-ever ischemic stroke and lasted 12 months compared
 to placebo were assessed through MoCA, NIHSS, mRS, and possible adverse effects.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06210646
Non-Device Trial